Annualized Recurring Revenue ('ARR') of $849 million Grew 47% year-over-yearRevenue of $250 million Grew 40% year-over-yearRaises Full Year ...
Clinical Program Highlights The LPLV milestone has been achieved in the AFFIRM-1 Phase 3 ... Net Loss: Net loss was $0.4 million, or $0.23 per basic and diluted share, for the year ended June 30, 2025 ...